NEW YORK, Jan 30 – Large Scale Biology and Biosite Diagnostics have combined efforts to develop protein chips, the companies announced Tuesday.

LSBC will pay Biosite an undisclosed sum to develop antibodies for proteins contained in LSBC’s Human Protein Index and Molecular Anatomy and Pathology database, with the two companies sharing in the profits from any diagnostic or protein chip product.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.